Bracco and ACIST Launch New Diagnostic System for Enhanced Cardiovascular Imaging

Bracco and ACIST Medical Systems Unveil the ACIST Pro™ Diagnostic System

In a significant advancement in medical imaging technology, Bracco and ACIST Medical Systems have announced the U.S. Food and Drug Administration (FDA) clearance for their latest innovation: the ACIST Pro™ Diagnostic System. This breakthrough in the advancement of contrast management technology is designed to enhance the safety, precision, and efficiency of imaging-guided cardiovascular procedures.

The ACIST Pro™ system represents an evolution of prior technology, specifically building upon the automated contrast delivery system, ACIST CVi®. The original system revolutionized the cardiac catheterization laboratory by replacing manual contrast injections with automated, real-time precision. The clinical implementation of the ACIST CVi® demonstrated significant benefits, including an average reduction of 45ml in contrast usage, a 30% decrease in contrast-induced acute kidney injury (CI-AKI), and a time-saving of five minutes per procedure, on average.

According to Dr. Fulvio Renoldi Bracco, Vice-Chairman and CEO of Bracco Imaging, the launch of the ACIST Pro™ system in the United States marks a milestone for both the company and the future of precision imaging in cath labs. "By enabling clinicians to move from uncertainty to confidence at the point of diagnosis, we are supporting more informed decisions aimed at enhancing patient outcomes," he noted. The introduction of this technology is expected to bring noticeable benefits to clinical practices, allowing healthcare professionals to deliver safer and more efficient care to their patients.

In addition, Brad Fox, CEO of ACIST Medical Systems, emphasized that the development of the ACIST Pro™ Diagnostic System was guided directly by the needs and feedback of clinicians throughout the process. This collaboration underscores the imperative to merge efficiency with physician safety within a unified framework. The system is tailored to provide precise delivery of contrast media during interventional cardiology procedures, facilitating consistently clear images that are critical for accurate diagnostics.

The ACIST Pro™ system made its debut in Japan in 2025 and subsequently gained approval in selected European markets after earning a CE mark under the European Medical Device Regulation (MDR) as of February 2026. With the system now available in the U.S. market, ACIST Medical Systems is reaffirming its commitment to continuous innovation in the field of vascular imaging technologies.

For clinicians and healthcare facilities looking to enhance their imaging efficiency, the ACIST Pro™ Diagnostic System promises to be a game-changer. It not only improves clarity in imaging but also aligns with the current push towards precision medicine, a movement that aims to tailor medical treatment to individual characteristics of each patient.

For more information on the ACIST Pro™ Diagnostic System, interested parties can visit ACIST's official website. Bracco Group, a global leader in diagnostic imaging since its formation in 1927, operates in over 100 countries and has a workforce of over 4,000 people, generating an annual turnover of around €2 billion, with a substantial portion derived from international markets. Their commitment to innovation in healthcare is further exemplified by investing approximately 9% of their turnover into research and development each year.

Healthcare professionals and stakeholders in the medical field should keep a close eye on the integration of ACIST's cutting-edge technology within their practices, as these advancements are poised to reshape cardiovascular imaging and treatment approaches in the near future.

For inquiries regarding Bracco’s products and detailed prescribing information, visit Bracco's official site.